This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D80.2 (Selective deficiency of immunoglobulin A [IgA]) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Selective IgA deficiency, isolated IgA deficiency, IgA agammaglobulinemia (former name), Selective IgA deficiency (sIgAD), IgA deficiency (IGAD1), β2A-aglobulinemia |
| C. Adult onset | Fairly likely to first manifest in adulthood — the deficiency itself is present from childhood, but because 85–90% are asymptomatic, it is commonly first discovered or becomes symptomatic in adulthood through blood donation, celiac disease testing, autoimmune disease evaluation, transfusion reactions, and so on. |
| 1. History | 1959 Heremans isolates IgA (β2A) → 1964 first report of β2A agammaglobulinemia in healthy adults → 1965 secretory IgA discovered → 1968 transfusion anaphylaxis due to anti-IgA antibodies reported → 1999 ESID/PAGID diagnostic criteria established. |
| 2. Causes | Mostly primary (unknown cause, genetic predisposition); secondary — drugs (phenytoin, carbamazepine, sulfasalazine, penicillamine, gold preparations, etc.), congenital infection (rubella, CMV), chromosome 18 abnormalities, lymphoid neoplasms, protein loss. |
| 3. Genetics | Polygenic, familial aggregation; strong association with the MHC 8.1 ancestral haplotype (HLA-A1-B8-DR3-DQ2); GWAS risk loci such as IFIH1 and CLEC16A; TNFRSF13B (TACI) variants; shares a genetic spectrum with CVID. |
| 4. General epidemiology | Most common primary immunodeficiency; Caucasians 1:143 to 1:965; very rare in East Asia (Japan about 1:18,000); no sex difference; risk markedly increased in first-degree relatives; 85–90% asymptomatic. |
| 5. Pathophysiology | Impaired terminal differentiation of IgA⁺ B cells into plasma cells (immature IgA⁺/IgD⁺ B cells); abnormal class-switching signals (TGF-β, APRIL–TACI, IL-10, IL-21); weakened mucosal defense and abnormal gut microbiota → infection and autoimmunity. |
| 6. Symptoms | Recurrent sinus, middle ear, bronchial, and pneumonia infections; chronic diarrhea (Giardia), celiac disease; asthma, allergic rhinitis, atopy; autoimmune diseases (ITP, SLE, thyroiditis, etc.); post-transfusion anaphylaxis. |
| 7. Signs | Serum IgA <7 mg/dL, normal IgG and IgM; decreased IgG2 subclass in some; anti-IgA antibodies; false-negative celiac IgA serology; bronchiectasis on chest HRCT; nodular lymphoid hyperplasia of the small intestine. |
| 8. Screening | No population screening; quantitative serum IgA/IgG/IgM (nephelometry) for recurrent infection, autoimmunity, celiac disease evaluation, transfusion reaction, or family history; measure total IgA at the same time during celiac testing; IgA screening of blood donors (in some countries). |
| 9. Diagnosis | Age 4 years or older, IgA <7 mg/dL (0.07 g/L), normal IgG and IgM, normal IgG antibody response to vaccines, exclusion of secondary causes and T-cell defects (ESID); repeated measurements, IgG subclass, specific antibody, and lymphocyte subset testing. |
| 10. Treatment | IgA replacement not possible; observe if asymptomatic; early antibiotics, prophylactic antibiotics, inactivated vaccines; low-IgA-content immunoglobulin if IgG subclass or specific antibody deficiency coexists; standard treatment of comorbid diseases; washed red blood cells. |
| 11. Prognosis | Mostly favorable; burden of bronchiectasis and autoimmune comorbidity in the symptomatic group; some progress to CVID; drug-induced and pediatric partial deficiency can recover; slightly increased risk of gastric cancer and lymphoma. |
| 12. Prevention | No primary prevention; infection prevention (vaccines, early treatment); transfusion safety (alert card, anti-IgA testing); periodic screening for autoimmunity and celiac disease; regular immunoglobulin follow-up for early detection of progression to CVID. |
| 13. References | Selective IgA deficiency: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management … and 9 other papers |
The history of IgA deficiency begins with the discovery of the immunoglobulin class IgA itself. In the late 1950s, Joseph F. Heremans of Belgium used immunoelectrophoresis to isolate a new protein distinct from IgG in the serum β-globulin fraction and named it β2A-globulin (1959). This protein later came to be called immunoglobulin A (IgA) under international nomenclature, and it gradually became clear that it is the immunoglobulin produced in the largest amount every day in the human body.
Descriptions of people lacking IgA first appeared in the early 1960s. In 1962, West, Hong, and Holland recorded cases in which IgA was undetectable while compiling immunoglobulin levels from newborns to adults, and in 1964 Rockey, Hanson, Heremans, and Kunkel reported "β2A-aglobulinemia in two healthy men," showing that a person can live without obvious clinical symptoms even when IgA is completely absent. At about the same time, absence of IgA was observed in patients with ataxia-telangiectasia, and it came to be recognized that IgA deficiency can occur both as an independent condition and as part of other syndromes.
In 1965, Thomas B. Tomasi and colleagues established that IgA in saliva, colostrum, and intestinal fluid is secretory IgA, a dimer joined by a J chain with secretory component attached. This discovery established the concept of mucosal immunity and provided the theoretical basis for explaining why respiratory and gastrointestinal infections recur in patients with IgA deficiency. In 1968, Vyas, Perkins, and Fudenberg reported that IgG antibodies against IgA (anti-IgA antibodies) form in IgA-deficient patients and can cause anaphylactic reactions after transfusion, and IgA deficiency emerged as an important risk factor in transfusion medicine.
In the 1970s–1980s, associations between IgA deficiency and autoimmune diseases such as celiac disease, systemic lupus erythematosus, rheumatoid arthritis, and type 1 diabetes, as well as with allergic diseases, were confirmed by numerous cohort studies. In 1981, Oxelius et al. reported that infections were especially frequent in the group of IgA-deficient patients with accompanying IgG2 subclass deficiency, and in the same year Conley and Cooper showed that patients' IgA⁺ B cells remain in an immature phenotype that also expresses IgD, proposing a pathophysiologic model of impaired terminal B-cell differentiation.
In 1999, the European Society for Immunodeficiencies (ESID) and the Pan-American Group for Immunodeficiency (PAGID) published diagnostic criteria of "serum IgA below 7 mg/dL at age 4 or older, normal IgG and IgM, and exclusion of other causes of hypogammaglobulinemia," and the basic framework of these criteria was retained in the 2019 ESID clinical working definitions. Since the 2000s, TACI (TNFRSF13B) variants have been found in both IgA deficiency and common variable immunodeficiency (CVID), and autoimmune risk loci such as IFIH1 and CLEC16A were identified by genome-wide association studies (GWAS) in 2010, establishing an understanding of IgA deficiency as a complex genetic disease on a continuum with CVID. The International Union of Immunological Societies (IUIS) classifies it in the category of "predominantly antibody deficiencies," and in Korea it is managed as an immunodeficiency disease eligible for rare disease Special Copayment Reduction.
Significance of the conceptual change
Initially, IgA deficiency was regarded as a "harmless laboratory abnormality found incidentally in healthy people," but as large cohorts and long-term follow-up studies accumulated, it was reappreciated as a heterogeneous group of diseases associated with various clinical outcomes, including infection, autoimmunity, allergy, malignancy, and progression to CVID. In particular, it has been emphasized that the asymptomatic group found in blood donor screening and the symptomatic group diagnosed in hospitals are different clinical populations, and today an approach that distinguishes the asymptomatic majority from the symptomatic minority and varies the intensity of follow-up has become standard.
Selective IgA deficiency is divided by cause into primary and secondary forms. Excluding secondary causes in the diagnostic process is essential, and drug-induced forms are clinically important in particular because recovery is possible after the causative drug is stopped.
Primary IgA deficiency
It accounts for the majority and is a multifactorial disease for which no single causative gene has been identified. Familial aggregation is evident, MHC haplotypes and multiple non-MHC gene polymorphisms act as predisposition, and environmental factors not yet clearly identified (early infection, gut microbial exposure, etc.) are added, which is understood to cause failure of differentiation into IgA plasma cells. IgA deficiency and CVID sometimes appear together within the same family, so the two diseases are considered to share a common genetic background.
Drug-induced IgA deficiency
Reported agents include the anticonvulsants phenytoin, carbamazepine, valproic acid, and lamotrigine, the rheumatic disease drugs sulfasalazine, D-penicillamine, gold preparations, and hydroxychloroquine, and others such as captopril, cyclosporine, and fenclofenac. IgA often recovers over several months to years after the drug is stopped, but in some it persists. Therefore, a detailed medication history is needed when diagnosing IgA deficiency.
Infection-related
Congenital rubella, congenital cytomegalovirus (CMV) infection, congenital toxoplasmosis, and Epstein-Barr virus (EBV) infection have been reported in association with IgA deficiency. In particular, intrauterine infection affects the period of B-cell development and can cause persistent deficiency.
Chromosomal abnormalities and associated syndromes
IgA deficiency accompanies chromosome 18 deletions (18q-, 18p-), ring chromosome 18, 22q11.2 deletion syndrome, Turner syndrome, ataxia-telangiectasia, and others. In this case the IgA deficiency should be interpreted as part of the phenotype of the whole syndrome, and when applying the ICD-10 code, the relationship to the primary diagnosis should also be considered.
Other secondary causes
Lymphoid neoplasms such as chronic lymphocytic leukemia and lymphoma, protein loss due to protein-losing enteropathy and nephrotic syndrome, the immune reconstitution period after bone marrow transplantation, and immunosuppressive treatment can cause secondary IgA decrease. In such cases, IgG and IgM are often decreased as well rather than IgA alone being low, which helps in differentiation. The diagnosis of primary deficiency is ultimately made after these causes have been systematically excluded.
Differentiating the cause in practice
The distinction between primary and secondary directly affects the treatment approach and the explanation of prognosis. If a drug-induced form is suspected, switch to an alternative drug when possible and re-measure IgA at 6–12 month intervals to check for recovery. When lymphoid neoplasms or protein loss are the cause, immunoglobulins other than IgA and albumin tend to decrease together, so performing protein electrophoresis, immunofixation electrophoresis, and quantitative urine protein together helps differentiation. In the syndrome-associated form, other immunologic defects of the syndrome (T-cell defects, etc.) should be evaluated.
Selective IgA deficiency is not a monogenic disease following Mendelian inheritance but a complex (polygenic) disease in which many susceptibility genes interact with environmental factors. In family studies, first-degree relatives of IgA-deficient patients are reported to have a risk of IgA deficiency tens of times higher than the general population, and some families show an autosomal dominant (incomplete penetrance) or recessive pattern. In addition, IgA deficiency, IgG subclass deficiency, and CVID are sometimes mixed within the same family, which is interpreted to mean that these diseases lie on a common genetic spectrum.
MHC (HLA) region
The strongest genetic risk factor is the major histocompatibility complex (MHC) region on the short arm of chromosome 6. In particular, the 8.1 ancestral haplotype (HLA-A1, B8, DR3, DQ2; DRB1*03:01–DQB1*02:01), common in people of Northern European descent, is strongly associated with IgA deficiency. This haplotype is also a risk haplotype for autoimmune diseases such as celiac disease, type 1 diabetes, and systemic lupus erythematosus, partly explaining why autoimmune disease is common in IgA-deficient patients. Conversely, HLA-DR15/DQ6 (DQB1*06:02) has been reported to act protectively. Within the MHC, the possible involvement not only of class II genes but also of the class III region (TNF, complement genes, etc.) has been raised.
Non-MHC susceptibility genes
In the 2010 genome-wide association study (GWAS) by Ferreira et al., IFIH1 (encoding the viral RNA sensor MDA5) and CLEC16A were identified as risk loci for IgA deficiency, and both genes are risk loci shared with autoimmune diseases such as type 1 diabetes. In subsequent large-scale analyses, additional loci such as PVT1, ATG13–AMBRA1, and AHI1 were reported, suggesting involvement of B-cell activation and autophagy pathways.
TNFRSF13B (TACI) variants
TACI is a receptor that receives APRIL and BAFF signals in B cells and promotes class switching to IgA and IgG and plasma cell differentiation. Heterozygous variants such as C104R and A181E are found in about 8–10% of CVID patients and in some IgA-deficient patients, but are also observed in healthy people, so they are interpreted as "modifiers" that raise disease susceptibility rather than as sole causative genes.
Clinical significance of genetic testing
At present, genetic testing is not required for the diagnosis of primary IgA deficiency. However, in atypical clinical presentations such as early onset, severe infections, multiple autoimmune diseases, or the presence of CVID patients within the family, a CVID/combined immunodeficiency gene panel can be considered to exclude other inborn errors of immunity. In family counseling, it is advisable to explain the increased risk of deficiency in first-degree relatives while also noting that the majority are asymptomatic.
Genotype-phenotype relationship
Even among family members with the same risk haplotype, the degree of deficiency and clinical features differ greatly, and one sibling may present with asymptomatic IgA deficiency and another with CVID. This shows that genetic factors determine disease susceptibility, but the actual phenotype is determined by interaction with environmental factors such as epigenetic regulation, infection exposure, and gut microbiota. In twin studies as well, the concordance of monozygotic twins is not complete, confirming a contribution of non-genetic factors.
Selective IgA deficiency is the most common primary immunodeficiency disease. However, because the majority are asymptomatic, the actual prevalence has been estimated mainly from blood donor screening studies and varies greatly by race and region.
Prevalence by race and region
In Caucasian populations it is reported at about 1:143 to 1:965, and in Western European and North American blood donor studies values around 1:500–1:700 are generally given. Relatively high prevalence has also been reported in parts of the Arabian Peninsula and in Iran. In contrast, it is markedly rarer in East Asia, at about 1:18,000 in Japanese blood donor studies and about 1 in several thousand in China, lower than in Caucasians. Population-based prevalence data in Korea are limited, but a frequency lower than in the West is presumed, similar to East Asian data, and because of this low frequency it is managed as a rare disease in Korea.
Sex and age
The difference in prevalence between males and females is not evident. Because IgA is physiologically low and matures late in infants and young children, it is not confirmed before age 4 and is followed as "partial or transient decrease." Therefore, the age at diagnosis is widely distributed from childhood to adulthood, and many cases are discovered incidentally in adulthood through tests done for other purposes.
Frequency of clinical features
About 85–90% of all patients are asymptomatic. In the symptomatic group, recurrent respiratory infection is the most common, and allergic disease is reported to accompany it in about 25–50% and autoimmune disease in about 20–30%. A study by Ludvigsson et al. that compared about 2,100 IgA-deficient individuals in a Swedish national cohort with controls showed a significantly higher risk of hospitalization and outpatient visits for various infections, including respiratory infection, in the IgA-deficient group, and the same research group's analysis confirmed an increased risk of many autoimmune diseases, including celiac disease, type 1 diabetes, rheumatoid arthritis, thyroid disease, and systemic lupus erythematosus.
Familial aggregation and related diseases
The frequency of IgA deficiency in first-degree relatives is markedly higher, and cases with concurrent CVID within a family are also reported. The frequency of IgA deficiency in celiac disease patients is 10–20 times higher than in the general population, reaching about 2–3%, which directly affects the interpretation of celiac screening tests. A high prevalence of IgA deficiency is also observed in groups of patients with type 1 diabetes and autoimmune thyroid disease.
Significance in domestic clinical practice
In Korea, the prevalence is lower than in the West, so clinicians have little opportunity to encounter IgA deficiency, and celiac disease is also rare, so discovery prompted by celiac testing is less frequent than in the West. Therefore, actively performing quantitative serum immunoglobulin testing when there are clinical clues such as recurrent sinus and lung infections, unexplained autoimmune cytopenia, or a severe allergic reaction after transfusion is the key to diagnosis. Because registration for rare disease Special Copayment Reduction presupposes that diagnostic criteria are met and secondary causes are excluded, repeated confirmation of test results is needed.
IgA is the immunoglobulin produced in the largest quantity in the human body, with about 60–70 mg/kg generated per day. Serum contains mainly monomeric IgA1, and mucosal secretions contain dimeric IgA (IgA1 and IgA2) joined by a J chain. Dimeric IgA binds to the polymeric immunoglobulin receptor (pIgR) on the basal surface of mucosal epithelial cells, crosses the cell (transcytosis), and is released onto the mucosal surface as secretory IgA together with the secretory component. Secretory IgA is responsible for "immune exclusion," neutralizing pathogens and toxins and blocking epithelial adhesion, and regulates the composition of the commensal gut microbial community.
Impaired B-cell differentiation
The core defect in selective IgA deficiency is failure of terminal differentiation into IgA-producing plasma cells. Patients' peripheral blood contains B cells expressing surface IgA, but these remain in an immature phenotype co-expressing IgD and fail to mature into IgA-secreting plasma cells. Abnormal transmission of or response to signals that induce class switch recombination — TGF-β, CD40L, the APRIL/BAFF–TACI pathway, IL-10, IL-21, and others — appears to be involved, and in some patients the IgA class-switched memory B cells themselves are reduced. Abnormalities in T-cell helper function and in the number and function of regulatory T cells (Treg) have also been reported.
Weakened mucosal defense and compensatory mechanisms
Even without secretory IgA, in most patients secretory IgM is compensatorily secreted through pIgR and replaces a substantial part of mucosal defense. When this compensation is insufficient, or when IgG2 subclass deficiency or a defect in specific polysaccharide antibody response accompanies it, recurrent sinus and lung infections occur. Recent studies have shown that the gut microbiota of IgA-deficient patients exhibits reduced diversity and imbalance (dysbiosis), and that compensatory IgM alone does not fully regulate commensal microorganisms.
Mechanisms of autoimmunity and allergy
It is explained that when mucosal barrier function is weakened, more food and microbial antigens enter the body, causing persistent immune stimulation and immune complex formation, which promotes autoimmunity and allergic sensitization. Added to this are the sharing of autoimmune risk genes such as the 8.1 haplotype, IFIH1, and CLEC16A, regulatory T-cell abnormalities, and hyperactivation of interferon signaling.
Anti-IgA antibodies
In patients with almost no IgA, IgA is recognized as a "foreign substance," and IgG (rarely IgE) anti-IgA antibodies may form. When blood products containing IgA (plasma, platelets, some immunoglobulin preparations) are administered, these antibodies can cause complement activation and mast cell degranulation, leading to anaphylaxis. However, the proportion of anti-IgA antibody carriers who actually experience a severe reaction is low, so there is controversy about the magnitude of the risk.
Pathophysiologic significance of accompanying IgG subclass deficiency
The constant region genes of IgA1 and IgA2 and of IgG2 and IgG4 lie adjacent to one another at the same IGH locus on chromosome 14, and class switching to them shares similar signaling pathways. For this reason, in some IgA-deficient patients IgG2 and IgG4 production is also reduced, and in this group IgG2 antibodies against encapsulated bacterial polysaccharides are lacking, so mucosal and systemic defenses are weakened at the same time. This is why this combination is the strongest risk factor for recurrent sinusitis, pneumonia, and bronchiectasis.
The majority (85–90%) of patients with selective IgA deficiency go through life without any particular symptoms and are found incidentally on tests done for other reasons. When symptoms are present, the clinical features can be broadly divided into five areas: infection, gastrointestinal disease, allergy, autoimmunity, and transfusion reaction.
Recurrent infections
Gastrointestinal symptoms
Allergic symptoms
Asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, and food allergy are more common than in the general population. Asthma is often exacerbated by infection and can be difficult to control.
Autoimmune symptoms
Bleeding tendency and anemia due to immune thrombocytopenia (ITP) and autoimmune hemolytic anemia, arthralgia and skin rash due to systemic lupus erythematosus and rheumatoid arthritis, type 1 diabetes, autoimmune thyroiditis (Hashimoto disease, Graves disease), vitiligo, Sjögren syndrome, and others may occur. It is also common for an autoimmune disease to be diagnosed before IgA deficiency, with the IgA deficiency revealed during the evaluation of the cause.
Transfusion-related reactions
When a patient with anti-IgA antibodies receives a blood product containing plasma components, an anaphylactic reaction with urticaria, dyspnea, and hypotension can occur abruptly. Such a transfusion reaction is sometimes the occasion on which IgA deficiency is first discovered.
Other
Rarely, fatigue, recurrent conjunctivitis, and oral ulcers are reported, and an association with central nervous system autoimmune disease (multiple sclerosis, etc.) has also been reported. In adulthood, it is not uncommon for symptoms to first appear on the occasion of a newly developed autoimmune disease or recurrent sinusitis.
Symptom patterns by age
In childhood, recurrent otitis media and upper respiratory tract infections are prominent, and the frequency of infection often decreases with growth. In adulthood, in contrast, chronic sinusitis, symptoms related to bronchiectasis, newly developed autoimmune disease, and allergic disease become the main clinical features. In symptomatic patients, when infections are severe or show an opportunistic pattern, or when lymphadenopathy, splenomegaly, or granulomatous lesions newly appear, it should be regarded as going beyond the scope of simple IgA deficiency, and progression to another immunodeficiency such as CVID should be evaluated.
Objective findings in selective IgA deficiency center on laboratory findings rather than physical examination. Physical findings are usually signs of accompanying infection, autoimmune, or allergic disease.
Physical examination findings
Immunologic test findings
Test findings related to comorbid diseases
When celiac disease is present, tissue transglutaminase IgA (tTG-IgA) and endomysial IgA antibodies are false-negative, so it is confirmed by positive tTG-IgG and deamidated gliadin peptide IgG (DGP-IgG) and villous atrophy on small intestinal biopsy. Depending on the autoimmune disease, antinuclear antibodies, antithyroid antibodies, thrombocytopenia, positive direct Coombs, and so on may appear.
Imaging and endoscopic findings
Mucosal thickening and air-fluid levels on sinus CT, bronchiectasis and bronchial wall thickening on chest high-resolution CT (HRCT), and nodular lymphoid hyperplasia or villous atrophy of the small intestine on endoscopy may be observed. Abdominal ultrasound is used as an adjunct to evaluate splenomegaly or intra-abdominal lymphadenopathy.
Cautions in interpreting tests
Some automated analyzers report the lower limit of IgA as "<0.25 g/L," making it difficult to distinguish complete from partial deficiency, so re-measurement with a method with a lower detection limit should be done if necessary. In addition, in IgA-deficient patients, IgA-based autoantibody tests (celiac antibodies, the IgA type of some antiphospholipid antibodies, etc.) may be false-negative, so IgG-type tests are preferred. After administration of immunoglobulin products, the interpretation of serum immunoglobulins is affected for several months.
There is no screening program for selective IgA deficiency in the general population, because the majority are asymptomatic and there is no treatment that corrects the deficiency itself. Instead, targeted screening based on clinical circumstances is recommended.
Situations in which screening is recommended
Screening methods
The first-line test is quantitative serum IgG, IgA, and IgM, measured by nephelometry or turbidimetry. If IgA is reported below the detection limit, IgA concentration can be measured by high-sensitivity ELISA as needed to distinguish complete deficiency (<0.05 mg/dL level) from partial deficiency. This is meaningful for assessing transfusion risk and selecting blood products with low IgA content. In infants and young children, age-specific reference values must be applied, and if IgA is low under age 4, it is not confirmed and is followed with repeat testing.
Screening in transfusion medicine
In the blood services of some countries, blood donors are screened for IgA, a registry of IgA-deficient donors is maintained, and plasma and platelets from IgA-deficient donors are supplied to patients with anti-IgA antibodies. In patients with a history of transfusion reaction and those expected to need repeated transfusion, IgA concentration and anti-IgA antibody testing before transfusion are considered.
Interpreting screening results
When decreased IgA is confirmed on screening, do not immediately diagnose primary deficiency; proceed to the diagnostic stage of repeat measurement, medication history, and evaluation of IgG subclasses and specific antibody response. In addition, asymptomatic individuals discovered by screening are told about the favorable course of the disease, and are also informed of precautions during transfusion and the need for regular follow-up.
Family screening in practice
Because asymptomatic deficiency is commonly found in first-degree relatives of IgA-deficient patients, family screening is particularly meaningful for members with recurrent infections or autoimmune disease and for members scheduled for surgery or transfusion. Family members found to have deficiency on screening are informed of precautions during transfusion and the need for regular follow-up, and are also told that the majority remain asymptomatic for life, to reduce unnecessary anxiety.
The diagnosis of selective IgA deficiency centers on quantitative serum immunoglobulins and proceeds through a process of excluding other immunodeficiencies and secondary causes.
ESID diagnostic criteria (clinical working definition)
When IgA is below −2 SD of the age-specific reference value but at or above 0.07 g/L, it is classified as partial IgA deficiency, and the clinical significance and course are evaluated individually.
Step 1: Confirmatory testing
Re-measure serum IgG, IgA, and IgM, and check the medication history (anticonvulsants, sulfasalazine, penicillamine, etc.) and secondary causes such as infection, tumor, and protein loss. Albumin, urine protein, and a complete blood count are also performed.
Step 2: Evaluation of accompanying antibody defects
Step 3: Cellular immunity and differential diagnosis
T, B, and NK cell counts and B-cell subsets (switched memory B cells, etc.) are evaluated by flow cytometry. The differential diagnosis includes CVID, transient hypogammaglobulinemia of infancy, ataxia-telangiectasia, 22q11.2 deletion syndrome, and hyper-IgM syndrome. In particular, when IgG is borderline low together with IgA deficiency, or when switched memory B cells are reduced, follow up with the possibility of progression to CVID in mind.
Step 4: Evaluation of comorbid diseases
Genetic testing
Not essential in typical primary IgA deficiency. An inborn errors of immunity gene panel is considered in atypical presentations such as early-onset severe infection, multiple autoimmunity, lymphoproliferation, or CVID within the family.
Common pitfalls in diagnosis
Measurement during recovery from acute infection or immediately after administration of immunoglobulin products, interpretation of pediatric results without applying age-specific reference values, and omission of the medication history are common causes of misdiagnosis. Errors are also common in which celiac disease is excluded by IgA-based tests in IgA-deficient patients, or partial deficiency is classified as complete deficiency. Even after the diagnosis is established, symptomatic patients should undergo periodic immunologic reassessment to check for changes in the diagnosis.
There is no treatment that corrects the deficiency itself in selective IgA deficiency; that is, IgA replacement therapy does not exist. This is because intravenously administered IgA is not secreted onto mucosa, has a short half-life, and carries a risk of forming anti-IgA antibodies. Therefore, treatment focuses on managing accompanying infection, allergic, and autoimmune diseases and preventing complications.
Asymptomatic patients
No specific treatment is needed; disease education, guidance on precautions during transfusion, and regular follow-up (immunoglobulins, screening for comorbid diseases) are provided.
Infection management
Immunoglobulin replacement therapy
Isolated IgA deficiency is not an indication for immunoglobulin replacement. However, in some patients in whom IgG subclass deficiency or a defect in specific polysaccharide antibody response accompanies it and severe, recurrent infections persist despite prophylactic antibiotics, IgG replacement is considered. In this case, select a preparation with low IgA content, check whether the patient has anti-IgA antibodies, and start the first dose slowly. Subcutaneous immunoglobulin (SCIG) has a relatively lower risk of systemic reactions and is an alternative.
Treatment of comorbid diseases
Transfusion management
Patients with anti-IgA antibodies or a history of transfusion reaction receive washed red blood cells and washed platelets or blood products from IgA-deficient donors. Autologous blood storage can be considered before planned surgery. Balanced judgment is required so that the risk of transfusion reaction is not exaggerated and necessary transfusion is not delayed.
Treatment goals and follow-up
The treatment goals for symptomatic patients are to reduce the frequency and severity of infections, to prevent chronic lung damage such as bronchiectasis, and to achieve early control of comorbid diseases. The number of infections per year, days of antibiotic use, number of hospitalizations, and changes in lung function are recorded to objectively assess the effect of prophylactic antibiotics or immunoglobulin replacement, and if the effect is insufficient, the diagnosis is reviewed to check for progression to CVID.
The overall prognosis of selective IgA deficiency is favorable. The majority of patients are asymptomatic and maintain a normal life expectancy and daily life. However, in some symptomatic patients there is a long-term burden from recurrent infections and comorbid diseases, and a minority progress to more severe antibody deficiency.
Infection-related prognosis
In patients with long-standing recurrent lower respiratory tract infections, chronic lung damage such as bronchiectasis and obliterative bronchiolitis can develop, which is a major determinant of quality of life and long-term prognosis. This risk is greatest in the group with accompanying IgG2 subclass deficiency or a defect in specific antibody response. In the Swedish national cohort study, the infection risk in the IgA-deficient group was significantly higher than in controls.
Progression to CVID
Some patients progress to common variable immunodeficiency (CVID) as IgG and IgM decrease during follow-up. In several cohorts, including the study by Aghamohammadi et al., some symptomatic IgA-deficient patients met CVID criteria within several years, and accompanying IgG subclass deficiency, reduced switched memory B cells, and the presence of CVID patients within the family were presented as risk factors for progression. Therefore, symptomatic patients should have IgG and IgM re-measured regularly.
Possibility of recovery
Partial IgA deficiency in children often normalizes with growth. The drug-induced form can recover after the causative drug is stopped, but recovery may take several months to years or may persist. In contrast, complete deficiency confirmed after age 4 generally persists for life.
Autoimmunity and malignancy
The presence of autoimmune disease affects long-term prognosis, and the course of the disease is determined by the severity of each autoimmune disease. There are reports of a slightly increased risk of gastric cancer and lymphoma, so new gastrointestinal symptoms or lymphadenopathy should be actively evaluated.
Mortality
In population-based studies, the risk of death after a diagnosis of IgA deficiency was observed to be somewhat higher than in the general population, but the increase is interpreted as being mainly related to the comorbid diseases (autoimmunity, infection, tumor) that prompted the diagnosis. There is no evidence that asymptomatic deficiency itself shortens life expectancy. Ultimately, prognosis depends on early detection and management of comorbid diseases, active treatment of infections, and monitoring for progression to CVID.
Summary of prognostic factors
Factors associated with poor prognosis include accompanying IgG2 subclass deficiency, decreased specific polysaccharide antibody response, reduced switched memory B cells, early-onset recurrent severe infections, multiple accompanying autoimmune diseases, and the presence of CVID patients within the family. Patients with these factors should preferably have immunologic and respiratory follow-up at shorter intervals. In contrast, asymptomatic deficiency discovered through blood donor screening and similar means generally follows a stable course over the long term.
There is currently no known way to prevent the occurrence of primary selective IgA deficiency itself. Therefore, prevention focuses on avoiding secondary deficiency, preventing complications, and early detection of progression.
Primary prevention: avoiding secondary causes and family counseling
When prescribing drugs that can cause decreased IgA (phenytoin, carbamazepine, sulfasalazine, penicillamine, etc.), if recurrent infections occur, check immunoglobulins and consider an alternative drug if needed. Prevention of intrauterine infection such as congenital rubella (checking rubella immunity and vaccination in women of childbearing age) also contributes to preventing secondary deficiency. Because of familial aggregation, immunoglobulin testing may be recommended for first-degree relatives of the patient, particularly family members with recurrent infections or autoimmune disease.
Secondary prevention: preventing infectious complications
Prevention of transfusion reactions
Diagnosed patients are asked to have "IgA deficiency" noted on a medical alert card or bracelet, and in situations where transfusion is anticipated, such as surgery or childbirth, anti-IgA antibodies are checked in advance and washed blood products or blood from IgA-deficient donors are prepared. When administering immunoglobulin products as well, a preparation with low IgA content is selected.
Tertiary prevention: early detection of comorbid diseases and progression
This systematic follow-up is a balanced strategy that avoids unnecessary treatment for the asymptomatic majority while preventing irreversible complications in the symptomatic minority.
Key points of patient education
Patient education should include the favorable course of the disease, the need for early medical care when infection occurs, informing healthcare staff of the IgA deficiency at the time of transfusion or administration of blood products, and the meaning of regular follow-up tests. In particular, in preparation for situations in which transfusion is needed in an emergency such as surgery, childbirth, or trauma, the patient should carry a document recording the diagnosis and the anti-IgA antibody test result.
Yazdani R, Azizi G, Abolhassani H, Aghamohammadi A. Selective IgA deficiency: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. Scandinavian Journal of Immunology. 2017;85(1):3–12. DOI: 10.1111/sji.12499. PMID: 27763681.
Yel L. Selective IgA deficiency. Journal of Clinical Immunology. 2010;30(1):10–16. DOI: 10.1007/s10875-009-9357-x.
Swain S, Selmi C, Gershwin ME, Teuber SS. The clinical implications of selective IgA deficiency. Journal of Translational Autoimmunity. 2019;2:100025. DOI: 10.1016/j.jtauto.2019.100025. PMID: 32743511.
Odineal DD, Gershwin ME. The epidemiology and clinical manifestations of autoimmunity in selective IgA deficiency. Clinical Reviews in Allergy & Immunology. 2020;58(1):107–133. DOI: 10.1007/s12016-019-08756-7.
Ludvigsson JF, Neovius M, Hammarström L. Risk of infections among 2100 individuals with IgA deficiency: a nationwide cohort study. Journal of Clinical Immunology. 2016;36(2):134–140. DOI: 10.1007/s10875-015-0230-9. PMID: 26739713.
Ludvigsson JF, Neovius M, Hammarström L. Association between IgA deficiency & other autoimmune conditions: a population-based matched cohort study. Journal of Clinical Immunology. 2014;34(4):444–451. DOI: 10.1007/s10875-014-0009-4.
Ferreira RC, Pan-Hammarström Q, Graham RR, et al. Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nature Genetics. 2010;42(9):777–780. DOI: 10.1038/ng.644.
Aghamohammadi A, Mohammadi J, Parvaneh N, et al. Progression of selective IgA deficiency to common variable immunodeficiency. International Archives of Allergy and Immunology. 2008;147(2):87–92. DOI: 10.1159/000135694.
Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Journal of Allergy and Clinical Immunology. 2015;136(5):1186–1205.e78. DOI: 10.1016/j.jaci.2015.04.049.
Justiz Vaillant AA, Wilson AM. Selective IgA deficiency. In: StatPearls. Treasure Island (FL): StatPearls Publishing. PMID: 30855793. NCBI Bookshelf.